Page last updated: 2024-11-06

(2S)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID60026
CHEMBL ID249263
CHEBI ID93476
SCHEMBL ID3182743
SCHEMBL ID22571
SCHEMBL ID1692510

Synonyms (58)

Synonym
SPECTRUM_001705
BSPBIO_002241
NCGC00178741-01
SPECTRUM5_001434
KBIOGR_001601
KBIO2_007321
KBIO3_001461
KBIOSS_002185
KBIO2_004753
KBIO2_002185
SPBIO_001887
SPECTRUM2_001674
SPECTRUM3_000641
SPECTRUM4_001121
SPECTRUM1504258
HMS2093E14
CHEMBL249263
(2s)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
HMS1922J03
nsc758695
pharmakon1600-01504258
CCG-39088
BRD-K84658672-001-01-4
SCHEMBL3182743
SCHEMBL22571
SCHEMBL1692510
105816-05-5
ent-nateglinide
AB01563019_01
l-nateglinide
J-001486
AKOS027263723
SR-05000001996-1
sr-05000001996
A1-02998
CHEBI:93476
SBI-0206770.P001
NCGC00389595-01
((1r,4s)-4-isopropylcyclohexane-1-carbonyl)-l-phenylalanine
CS-0272014
Z1501485358
eim17-02523
BRD-K84658672-001-03-0
n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-l-phenylalanine (nateglinide l-phenylalanine isomer)
nateglinide impurity b [ep impurity]
(2s)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
EN300-117267
l-phenylalanine, n-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-
l-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-
e9v3s85rhy ,
n-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-l-phenylalanine
unii-e9v3s85rhy
nateglinide impurity b [ep]
nateglinide impurity b
(s)-2-(trans-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
1163241-28-8
(2s)-3-phenyl-2-{[(1s,4s)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid
EN300-37158629

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID364052Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 10 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364051Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 1 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364053Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 100 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID132162Hypoglycemic activity causing more than a 20% blood glucose decrease in fasting mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's4 (44.44)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]